



www.cgen.com

Contact:
Ms Tsipi Keren Lehrer
 tsipikl@compugen.co.il

Compugen's mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industry. The Company's powerful discovery engines enable the predictive discovery of numerous potential therapeutics and diagnostic biomarkers. The Company's primary commercialization pathway for its therapeutic and diagnostic product candidates is to enter into milestone and revenue sharing out-licensing and joint development agreements with leading companies.



Success Story of Compugen Ltd.



www.smesgolifesciences.org

EU FP Project : SIMAP

Project Title: Simulation modelling of the MAP kinase pathway 

Call details:

Priority : IST
 Submission date : 22.04.2005
 Reference : FP6-2004 IST-4-2.4.11

Project type:

Integrated Project
 Network of Excellence
 Specific Targeted Research Project

Website: www.simap-project.org

Project Abstract: The objective of SIMAP is to develop a comprehensive simulation of a biochemical model of the EGFR-MAP kinase pathway in connection to clinical phenotype. SIMAP will rely on the OMICS revolution by combining mechanistic modelling of cancer related pathway behaviour, accompanied by new mining techniques and integrated with clinical data. Use of the SIMAP simulation will allow drastic decrease of costs or timescales of treatments and support better patient cancer treatment and diagnosis. The project is led by a drug and diagnostic discovery SME and an interdisciplinary industrial and academic leading teams of investigators

Consortium composition : 9 partners from 6 countries

<i>SME</i> Compugen Ltd	IL	Istituto Nazionale Per Lo Studio E La Cura Dei Tumori	IT
Artic Israel Company Ltd	IL	Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V.	DE
<i>SME</i> Aureus Pharma	FR	The University of Glasgow	UK
Consejo Superior de Investigaciones Cientificas	ES	Weizmann Institute of Science	IL
Institut De Recerca Hospital Universitari Vall De Hebron	ES		

Compugen in SIMAP

Compugen is the coordinator of SIMAP.

Dr. Alex Kotzer, CEO, Compugen elaborates on the expectations: "Compugen has already established a pipeline of novel splice variants both for therapeutic and diagnosis purposes. We have licensed our discovery engines in the past to big Pharmaceutical companies such as Pfizer, Novartis and Abbott Laboratories and established pipeline deals with Diagnostic Products Corporation. Compugen will use the new generic tools to mine pathways of interest that are related to its patented pipeline of novel splice variants. The utility developed will assist Compugen in early stage development stages of pre-clinical and clinical testing for its existing potential

therapeutics proteins. The tools and the model will be incorporated into Compugen's unique mining tools and might give rise to some novel diagnostics and therapeutic compounds and compounds combination."

Intellectual Property Rights (IPR) are taken care of in the Consortium agreements.

SMEs go LifeSciences partner (ISERD) assisted Compugen in various ways such as aspects of the submission procedure, the forms and paperwork, and most importantly, was available for consultation on all sorts of administrative and IPR questions.

Previous involvement in European projects: Participates in RIBOSYS as participant.

SMEs go LifeSciences partner :

ISERD - www.iserd.org.il
 Contact Person : Dr. Eva Rockman - eva@iserd.org.il

